Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
NEW YORK, Sept. 27, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased MGT Capital Investments, Inc. (NYSE MKT:MGT) securities between May 9, 2016 and September 20, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/mgt-capital-investments-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company was engaging in and/or had engaged in conduct that would result in an SEC investigation; (b) the SEC investigation and the underlying conduct would cause the New York Stock Exchange to refuse to list the Company’s 43.8 million shares required for the D-Vasive merger; and (c) as such, the D-Vasive merger would likely not be completed.
On September 19, 2016, MGT announced the receipt of a subpoena from the SEC requesting information from the Company. In addition, the Company announced that the NYSE has refused to list the shares required to close MGT’s acquisition of D-Vasive Inc. Following this news, shares of MGT fell from a close of $2.52 the previous day to a close of $1.89 per share on September 20, 2016.
If you suffered a loss in MGT you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/mgt-capital-investments-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
